Newbury Pharmaceuticals was founded in 2020 by Swedish Karl Karlsson. We are rapidly growing and offer a product portfolio of specialty pharma medicines with focus on the Scandinavian markets. The portfolio strategy includes niche and value-added small molecules, products based on peptide technology as well as biosimilars in a variety of therapeutic categories. The portfolio consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology representing more than 70 percent. The company was listed on Nasdaq First North, February 2022.